PPARα: An Emerging Target of Metabolic Syndrome, Neurodegenerative and Cardiovascular Diseases

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2023 Jan 2

PMID 36589809

Authors

Yijun Lin

Yan Wang

Pei-Feng Li

Affiliations

Soon will be listed here.

Abstract

Peroxisome proliferator-activated receptor α (PPARα) is a ligand-activated transcription factor that is involved in lipid metabolism of various tissues. Different metabolites of fatty acids and agonists like fibrates activate PPARα for its transactivative or repressive function. PPARα is known to affect diverse human diseases, and we focus on advanced studies of its transcriptional regulation in these diseases. In MAFLD, PPARα shows a protective function with its upregulation of lipid oxidation and mitochondrial biogenesis and transcriptional repression of inflammatory genes, which is similar in Alzheimer's disease and cardiovascular disease. Activation of PPARα also prevents the progress of diabetes complications; however, its role in diabetes and cancers remains uncertain. Some PPARα-specific agonists, such as Wy14643 and fenofibrate, have been applied in metabolic syndrome treatment, which might own potential in wider application. Future studies may further explore the functions and interventions of PPARα in cancer, diabetes, immunological diseases, and neurodegenerative disease.

Citing Articles

Overexpression of Apolipoprotein A-I Alleviates Insulin Resistance in MASLD Mice Through the PPARα Pathway.

Wang Y, Zhang Y, Wang Y Int J Mol Sci. 2025; 26(3).

PMID: 39940822 PMC: 11817368. DOI: 10.3390/ijms26031051.

Identification of Endometriosis Pathophysiologic-Related Genes Based on Meta-Analysis and Bayesian Approach.

Kang J, Ahn K, Oh J, Lee T, Hwang S, Uh Y Int J Mol Sci. 2025; 26(1.

PMID: 39796277 PMC: 11720405. DOI: 10.3390/ijms26010424.

Palmitoylethanolamide in Postmenopausal Metabolic Syndrome: Current Evidence and Clinical Perspectives.

Medoro A, Davinelli S, Fogacci F, Alfieri S, Tiso D, Cicero A Nutrients. 2025; 16(24.

PMID: 39770936 PMC: 11677032. DOI: 10.3390/nu16244313.

Vitamin D supplementation alleviates high fat diet-induced metabolic associated fatty liver disease by inhibiting ferroptosis pathway.

Miao Y, Jiang Z, Song H, Zhang Y, Chen H, Liu W Eur J Nutr. 2024; 64(1):50.

PMID: 39708119 DOI: 10.1007/s00394-024-03554-0.

The protective effects of fisetin in metabolic disorders: a focus on oxidative stress and associated events.

Sattari M, Amri J, Shahaboddin M, Sattari M, Tabatabaei-Malazy O, Azmon M J Diabetes Metab Disord. 2024; 23(2):1753-1771.

PMID: 39610486 PMC: 11599505. DOI: 10.1007/s40200-024-01502-7.

References

Mirza A, Althagafi I, Shamshad H . Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications. Eur J Med Chem. 2019; 166:502-513. DOI: 10.1016/j.ejmech.2019.01.067. View

Bougarne N, Weyers B, Desmet S, Deckers J, Ray D, Staels B . Molecular Actions of PPARα in Lipid Metabolism and Inflammation. Endocr Rev. 2018; 39(5):760-802. DOI: 10.1210/er.2018-00064. View

Issemann I, Green S . Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990; 347(6294):645-50. DOI: 10.1038/347645a0. View

Fillmore N, Mori J, Lopaschuk G . Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br J Pharmacol. 2013; 171(8):2080-90. PMC: 3976623. DOI: 10.1111/bph.12475. View

Saez-Orellana F, Octave J, Pierrot N . Alzheimer's Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor α. Cells. 2020; 9(5). PMC: 7290654. DOI: 10.3390/cells9051215. View

Lee Y, Jang H, Kim S, Choi S, Khim K, Eom H . Hepatic promotes nonalcoholic fatty liver disease by suppressing . Elife. 2021; 10. PMC: 8758141. DOI: 10.7554/eLife.70472. View

Finck B, Lehman J, Leone T, Welch M, Bennett M, Kovacs A . The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002; 109(1):121-30. PMC: 150824. DOI: 10.1172/JCI14080. View

Aibara D, Takahashi S, Yagai T, Kim D, Brocker C, Levi M . Gene repression through epigenetic modulation by PPARA enhances hepatocellular proliferation. iScience. 2022; 25(5):104196. PMC: 9036120. DOI: 10.1016/j.isci.2022.104196. View

Wan C, Wong C, Pin W, Wong M, Kwok C, Chan R . Chlorogenic acid exhibits cholesterol lowering and fatty liver attenuating properties by up-regulating the gene expression of PPAR-α in hypercholesterolemic rats induced with a high-cholesterol diet. Phytother Res. 2012; 27(4):545-51. DOI: 10.1002/ptr.4751. View

10.

Kim Y, Lim J, Kim M, Kim E, Yoon H, Shin S . The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes. J Am Soc Nephrol. 2018; 29(4):1108-1127. PMC: 5875945. DOI: 10.1681/ASN.2017060627. View

11.

Sun N, Shen C, Zhang L, Wu X, Yu Y, Yang X . Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance. Gut. 2020; 70(11):2183-2195. PMC: 8515101. DOI: 10.1136/gutjnl-2020-321774. View

12.

Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F . Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 2015; 21(5):739-46. DOI: 10.1016/j.cmet.2015.04.004. View

13.

Kawasaki M, Kambe A, Yamamoto Y, Arulmozhiraja S, Ito S, Nakagawa Y . Elucidation of Molecular Mechanism of a Selective PPARα Modulator, Pemafibrate, through Combinational Approaches of X-ray Crystallography, Thermodynamic Analysis, and First-Principle Calculations. Int J Mol Sci. 2020; 21(1). PMC: 6981837. DOI: 10.3390/ijms21010361. View

14.

Zhu Y, Wang X, Zhou X, Ding L, Liu D, Xu H . DNMT1-mediated PPARα methylation aggravates damage of retinal tissues in diabetic retinopathy mice. Biol Res. 2021; 54(1):25. PMC: 8348846. DOI: 10.1186/s40659-021-00347-1. View

15.

Flavell D, Torra I, Jamshidi Y, Evans D, Diamond J, Elkeles R . Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia. 2000; 43(5):673-80. DOI: 10.1007/s001250051357. View

16.

Juge-Aubry C, Hammar E, PERNIN A, Takeshita A, Chin W, Burger A . Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent trans-activating domain. J Biol Chem. 1999; 274(15):10505-10. DOI: 10.1074/jbc.274.15.10505. View

17.

Gross B, Pawlak M, Lefebvre P, Staels B . PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol. 2016; 13(1):36-49. DOI: 10.1038/nrendo.2016.135. View

18.

Chou C, Haluzik M, Gregory C, Dietz K, Vinson C, Gavrilova O . WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem. 2002; 277(27):24484-9. DOI: 10.1074/jbc.M202449200. View

19.

Gearing K, Gottlicher M, Teboul M, Widmark E, Gustafsson J . Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci U S A. 1993; 90(4):1440-4. PMC: 45889. DOI: 10.1073/pnas.90.4.1440. View

20.

Jiang B, Wang Y, Wang H, Song L, Huang C, Zhu Q . Antidepressant-like effects of fenofibrate in mice via the hippocampal brain-derived neurotrophic factor signalling pathway. Br J Pharmacol. 2016; 174(2):177-194. PMC: 5192965. DOI: 10.1111/bph.13668. View